RhoVac AB announced that RhoC is the target protein that the company uses in its ongoing immuno-oncology clinical trial in prostate cancer, BRaVac. New findings about RhoC's function in the migration of cancer cells have been published in the scientific journal Cancer Cell International, thus giving RhoVac's candidate broader support from the international scientific community.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.53 SEK | +51.43% | -.--% | -6.03% |
Mar. 28 | Chosa Oncology Names CFO, Chief Commercial Officer | MT |
Mar. 28 | CHOSA Oncology AB Announces Chief Financial Officer Changes | CI |
1st Jan change | Capi. | |
---|---|---|
-6.03% | 3.14M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CHOSA Stock
- News Chosa Oncology AB
- RhoVac AB Announces Scientific Publication Supports its Cancer Treatment Method